Cohen Klingenstein’s ResMed RMD Stock Holding History

Cohen Klingenstein’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Hold	5,900	–	–	0.03%	152
2026 Q1	$1.32M	Hold	5,900	–	–	0.04%	145
2025 Q4	$1.42M	Hold	5,900	–	–	0.04%	145
2025 Q3	$1.62M	Hold	5,900	–	–	0.05%	139
2025 Q2	$1.52M	Hold	5,900	–	–	0.05%	139
2025 Q1	$1.32M	Hold	5,900	–	–	0.05%	142
2024 Q4	$1.35M	Hold	5,900	–	–	0.05%	144
2024 Q3	$1.44M	Sell	5,900 -446	-7%	-$99.7K	0.05%	152
2024 Q2	$1.21M	Hold	6,346	–	–	0.04%	157
2024 Q1	$1.26M	Hold	6,346	–	–	0.05%	157
2023 Q4	$1.09M	Hold	6,346	–	–	0.04%	162
2023 Q3	$938K	Hold	6,346	–	–	0.04%	166
2023 Q2	$1.39M	Hold	6,346	–	–	0.06%	144
2023 Q1	$1.39M	Hold	6,346	–	–	0.07%	142
2022 Q4	$1.32M	Hold	6,346	–	–	0.07%	145
2022 Q3	$1.39M	Hold	6,346	–	–	0.07%	135
2022 Q2	$1.33M	Hold	6,346	–	–	0.07%	139
2022 Q1	$1.54M	Hold	6,346	–	–	0.06%	137
2021 Q4	$1.65M	Sell	6,346 -569	-8%	-$148K	0.07%	139
2021 Q3	$1.82M	Hold	6,915	–	–	0.08%	133
2021 Q2	$1.71M	Hold	6,915	–	–	0.07%	142
2021 Q1	$1.34M	Hold	6,915	–	–	0.06%	152
2020 Q4	$1.47M	Hold	6,915	–	–	0.07%	140
2020 Q3	$1.19M	Hold	6,915	–	–	0.07%	148
2020 Q2	$1.33M	Hold	6,915	–	–	0.08%	135
2020 Q1	$1.02M	Hold	6,915	–	–	0.08%	143
2019 Q4	$1.07M	Hold	6,915	–	–	0.06%	156
2019 Q3	$934K	Hold	6,915	–	–	0.06%	168
2019 Q2	$844K	Hold	6,915	–	–	0.06%	151
2019 Q1	$719K	Hold	6,915	–	–	0.05%	129
2018 Q4	$787K	Hold	6,915	–	–	0.12%	101
2018 Q3	$798K	Hold	6,915	–	–	0.1%	109
2018 Q2	$716K	Hold	6,915	–	–	0.1%	115
2018 Q1	$681K	Hold	6,915	–	–	0.1%	116
2017 Q4	$586K	Hold	6,915	–	–	0.08%	123
2017 Q3	$532K	Hold	6,915	–	–	0.08%	123
2017 Q2	$538K	Hold	6,915	–	–	0.08%	123
2017 Q1	$498K	Hold	6,915	–	–	0.08%	127
2016 Q4	$429K	Hold	6,915	–	–	0.07%	135
2016 Q3	$448K	Hold	6,915	–	–	0.08%	129
2016 Q2	$437K	Hold	6,915	–	–	0.08%	130
2016 Q1	$400K	Sell	6,915 -490	-7%	-$27.7K	0.08%	136
2015 Q4	$398K	Hold	7,405	–	–	0.07%	131
2015 Q3	$377K	Hold	7,405	–	–	0.07%	135
2015 Q2	$417K	Hold	7,405	–	–	0.08%	134
2015 Q1	$532K	Hold	7,405	–	–	0.1%	120
2014 Q4	$415K	Sell	7,405 -1,051	-12%	-$54.9K	0.08%	135
2014 Q3	$417K	Hold	8,456	–	–	0.07%	132
2014 Q2	$428K	Hold	8,456	–	–	0.08%	133
2014 Q1	$378K	Hold	8,456	–	–	0.08%	138
2013 Q4	$398K	Sell	8,456 -104	-1%	-$5.26K	0.08%	132
2013 Q3	$452K	Hold	8,560	–	–	0.1%	126
2013 Q2	$386K	Buy	+8,560	New	+$406K	0.09%	130

Other funds holding RMD

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TIA

Tandem Investment Advisors Charleston, South Carolina $1.49B AUM 12.33% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM

Aware Super Sydney, Australia $7.06B AUM

TIM

Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Cohen Klingenstein's RMD Position: Q2 2026 in Review

Cohen Klingenstein held its ResMed (RMD) position steady in Q2 2026 at 5,900 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #152.

Cohen Klingenstein first reported a position in RMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.82M in Q3 2021. 317 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Cohen Klingenstein held 5,900 shares of ResMed worth $1.15M as of Q2 2026.
Cohen Klingenstein left its ResMed share count unchanged in Q2 2026.
ResMed made up 0.03% of Cohen Klingenstein's portfolio in Q2 2026, its #152 holding.
Cohen Klingenstein first reported a position in ResMed in Q2 2013 and has held it in 53 quarters since.
Cohen Klingenstein's ResMed position peaked at $1.82M in Q3 2021.
317 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Cohen Klingenstein's 13F filing for Q2 2026, filed 15 Jul 2026.